Three self-reported prevalent symptoms among people with multiple sclerosis (MS) – fatigue, mobility issues, and cognitive impairment – are…
Articles by Andrea Lobo, PhD
A research project to explore the genetic connection between the Epstein-Barr virus (EBV) and the risk of developing multiple…
Autologous hematopoietic stem cell transplant (aHSCT) could slow disease progression in people with relapsing-remitting multiple sclerosis (RRMS), according to…
About 62% of multiple sclerosis (MS) patients use disease-modifying therapies (DMTs) before and during pregnancy, and the medications…
A person’s total number of visits to multiple sclerosis (MS) clinics is not associated with a lower risk of…
Blood levels of a protein called GFAP, which reflects the activation and damage to support cells in the brain and…
Mitochondrial abnormalities, or problems in the powerhouses of cells, seem to be a main contributor to the death of important…
A multicenter Phase 2a clinical trial testing foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) has…
Aetna Healthcare has agreed to reimburse Helius Medical Technologies’ PoNS device, short for Portable Neuromodulation Stimulator, which uses electrical…
Four Canadian nurses are among the 11 recipients of this year’s International Nightingale Awards, which support innovative projects aimed…
Ocrevus (ocrelizumab) appears to be safe and effective for children and adolescents with multiple sclerosis (MS), according to…
Wandercraft has launched Walk in New York, a new rehabilitation center that offers access to its advanced mobility…
The Multiple Sclerosis Association of America (MSAA) will host its 11th annual Improving Lives Benefit on May 14…
While a four-month progressive resistance training program improved muscle strength in people with secondary progressive multiple sclerosis  (SPMS) in…
Intimacy and sexuality among people with multiple sclerosis (MS) will be the focus of this year’s Holistic Health and…
Medicaid coverage for people with multiple sclerosis (MS) in the U.S. is associated with worse disease outcomes — including more…
Kyverna Therapeutics’ CAR T-cell therapy candidate KYV-101 was deemed safe and well tolerated, and showed preliminary signs of efficacy,…
A multicenter Phase 2a clinical trial testing Tiziana Life Sciences’ foralumab nasal spray in people with nonactive secondary progressive…
Fampridine, which is approved to improve walking in people with multiple sclerosis (MS), and the disease-modifying therapy Ocrevus…
The U.S. Food and Drug Administration (FDA) has approved a prefilled syringe format for Ani Pharmaceuticals’ purified Cortrophin Gel…
Disability progression independent of relapse activity, or PIRA, in the earliest stages of relapsing-remitting multiple sclerosis (RRMS) is associated…
Note: This story was updated March 6, 2025, to clarify the specific disability measures and results assessed in each…
A new model that combines genetic and symptom-based risk scores to predict the development of multiple sclerosis (MS) could…
Tiziana Life Sciences is partnering with a contract development and manufacturing organization with expertise in intranasal drugs to accelerate the…
Four more people with nonactive secondary progressive multiple sclerosis (SPMS) have received foralumab nasal spray — Tiziana Life…
Using Ocrevus (ocrelizumab) as a first-line treatment for early-stage relapsing forms of multiple sclerosis (MS) is significantly better…
Switching from anti-CD20 medications to less effective fumarate therapies is linked to reduced healthcare visits and costs related to infections…
Enigma Biomedical has entered into an agreement with Neuraly to use its PET imaging tracer PMI04 to visualize…
Patient enrollment has been completed ahead of schedule in a Phase 2 clinical trial evaluating Contineum Therapeutics‘ PIPE-307, an…
IMP761, an experimental immunotherapy Immutep is developing for multiple sclerosis (MS) and other autoimmune conditions, has shown a…